| 1 |
Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J]. Gut, 2002, 50(1): 123-128.
|
| 2 |
Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocelhlar carcinoma[J]. Int J Hepatol, 2013：419302.
|
| 3 |
European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485.
|
| 4 |
Thorat A, Lee CF, Wu TH, et al. Safety of transarterial chemoembolization as bridging therapy in HCC patients with hyperbilirubinemia on the waiting list for liver transplantation: a centre experience[J]. Hepatogastroenterology, 2012, 60(128): 2076-2079.
|
| 5 |
Pompili M, Francica G, Ponziani Fit, et al. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation[J]. World J Gastroenterol, 2013, 19(43): 7515-7530.
|
| 6 |
Yu CY, Ou HY, Weng CC, et al. Drug-eluting bead transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before living-donor liver transplantation[J]. Transplant Proc, 2016，48(4)：1045-1048.
|
| 7 |
Lai Q, Vitale A, Iesari S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl, 2019, 25(7)：1023-1033.
|
| 8 |
王浩， 高海军， 伊正甲， 等. 载药微球化疗栓塞治疗在肝癌肝移植术前应用的现状与进展[J]. 国际生物医学工程杂志， 2020, 43(3)：255-259.
|
| 9 |
Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation[J]. Hepatology, 2005, 41(5): 1130-1137.
|
| 10 |
Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study[J]. Ann Surg, 2004, 240(5): 900-909.
|
| 11 |
Cheung TT, Fan ST, Chan SC, et al. High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients[J]. WJG, 2013, 19(20): 3083-3092.
|
| 12 |
Chok KS, Cheung TT, Lo RC，et al. Pilot study of high-intensity focused ultrasound ablation as abridging therapy for hepatocellular carcinoma patients wait-listed for liver trailsplantation[J]. Liver Transpl, 2014, 20(8): 912-921.
|
| 13 |
汪国营. 肝癌肝移植新进展——2019年ILTS年会速递[J]. 器官移植， 2020, 11(1): 47-53.
|
| 14 |
Wong TC, Lee VH, Law AL, et al. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant[J]. Hepatology, 2021, 74(5): 2580-2594.
|
| 15 |
邓斐文， 陈焕伟， 甄作均. 经颈静脉肝内门体分流术后肝移植单中心经验总结[J/CD]. 实用器官移植电子杂志， 2020, 8(4)：261-266.
|
| 16 |
杨镇， 裘法祖. 门脉高压症外科治疗中应重视的几个问题[J]. 肝胆外科杂志， 2000, 8(1)：1-2.
|
| 17 |
冷希圣. 肝移植时代如何看待门静脉高压症的断流手术[J]. 中国现代普通外科进展， 2007, 10(1)：1-4.
|
| 18 |
Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1)：568.
|
| 19 |
Maggiore U, Pascual J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients[J]. Adv Chronic Kidney Dis, 2016, 23(5)：312-316.
|
| 20 |
Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient？[J]. Am J Transplant, 2020, 20(3)：879-883.
|
| 21 |
Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66：101386.
|
| 22 |
崔春晓， 杨柳晓， 王颖， 等．肝癌患者肝移植术前使用PD-1抑制剂对移植后排斥反应的影响[J]. 中国临床医学， 2020, 27(3)：444-447.
|
| 23 |
Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation？[J]. Am J Transplant, 2021, 21(5)：1979-1980.
|
| 24 |
Díaz-Sánchez A, Matilla A, Núñez O, et al. Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival[J]. Gastroenterol Hepatol, 2010，33(3)：155-164.
|
| 25 |
Clavien PA, Lesertel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1)：e11-e22.
|
| 26 |
Cescon M, Cucchetti A, Ravaioli M, et al. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate[J]. J Hepatol, 2013, 58(3)：609-618.
|
| 27 |
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1)：358-380.
|